{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:07:24Z","timestamp":1774645644431,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T00:00:00Z","timestamp":1403222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11914-014-0220-5","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T13:19:21Z","timestamp":1403183961000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Sclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments"],"prefix":"10.1007","volume":"12","author":[{"given":"Igor","family":"Fijalkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline","family":"Boudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Van Hul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,20]]},"reference":[{"issue":"9773","key":"220_CR1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276\u201387.","journal-title":"Lancet"},{"issue":"5","key":"220_CR2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.beem.2008.08.007","volume":"22","author":"S Ferrari","year":"2008","unstructured":"Ferrari S. Human genetics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22(5):723\u201335.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"13","key":"220_CR3","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/hmg\/9.13.2059","volume":"9","author":"U Kornak","year":"2000","unstructured":"Kornak U et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet. 2000;9(13):2059\u201363.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"220_CR4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrendo.2013.137","volume":"9","author":"C Sobacchi","year":"2013","unstructured":"Sobacchi C et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522\u201336. Comprehensive and up-to-date review on the heterogeneous group of Osteopetroses.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"220_CR5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(01)00206-9","volume":"104","author":"U Kornak","year":"2001","unstructured":"Kornak U et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104(2):205\u201315.","journal-title":"Cell"},{"key":"220_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nm842","volume":"9","author":"N Chalhoub","year":"2003","unstructured":"Chalhoub N et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med. 2003;9:399\u2013406.","journal-title":"Nat Med"},{"key":"220_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM198507183130302","volume":"313","author":"WS Sly","year":"1985","unstructured":"Sly WS et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med. 1985;313:139\u201345.","journal-title":"N Engl J Med"},{"issue":"1","key":"220_CR8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajhg.2008.06.015","volume":"83","author":"MM Guerrini","year":"2008","unstructured":"Guerrini MM et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008;83(1):64\u201376.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"220_CR9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","volume":"39","author":"C Sobacchi","year":"2007","unstructured":"Sobacchi C et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39(8):960\u20132.","journal-title":"Nat Genet"},{"issue":"20","key":"220_CR10","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/hmg\/11.20.2371","volume":"11","author":"A Smahi","year":"2002","unstructured":"Smahi A et al. The NF-kappaB signaling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 2002;11(20):2371\u20135.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"220_CR11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1172\/JCI30328","volume":"117","author":"L Wesenbeeck Van","year":"2007","unstructured":"Van Wesenbeeck L et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007;117(4):919\u201330.","journal-title":"J Clin Invest"},{"issue":"4","key":"220_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/jmedgenet-2011-100520","volume":"49","author":"M Aker","year":"2012","unstructured":"Aker M et al. An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet. 2012;49(4):221\u20136.","journal-title":"J Med Genet"},{"issue":"25","key":"220_CR13","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1093\/hmg\/10.25.2861","volume":"10","author":"E Cleiren","year":"2001","unstructured":"Cleiren E et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet. 2001;10(25):2861\u20137.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"220_CR14","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1530\/EJE-13-0136","volume":"169","author":"J Bollerslev","year":"2013","unstructured":"Bollerslev J et al. Autosomal dominant osteopetrosis revisited: lessons from recent studies. Eur J Endocrinol. 2013;169(2):R39\u201357.","journal-title":"Eur J Endocrinol"},{"issue":"5279","key":"220_CR15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","volume":"273","author":"BD Gelb","year":"1996","unstructured":"Gelb BD et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236\u20138.","journal-title":"Science"},{"issue":"1","key":"220_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","volume":"70","author":"RD Little","year":"2002","unstructured":"Little RD et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11\u20139.","journal-title":"Am J Hum Genet"},{"issue":"20","key":"220_CR17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"Boyden LM et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"220_CR18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1086\/497706","volume":"77","author":"M Ai","year":"2005","unstructured":"Ai M et al. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet. 2005;77(5):741\u201353.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"220_CR19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537\u201343.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"220_CR20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577\u201389.","journal-title":"Am J Hum Genet"},{"issue":"22","key":"220_CR21","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","volume":"286","author":"O Leupin","year":"2011","unstructured":"Leupin O et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286(22):19489\u2013500.","journal-title":"J Biol Chem"},{"issue":"2","key":"220_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans W et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91\u20137.","journal-title":"J Med Genet"},{"issue":"5","key":"220_CR23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00439-011-0947-3","volume":"129","author":"SJ Kim","year":"2011","unstructured":"Kim SJ et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet. 2011;129(5):497\u2013502.","journal-title":"Hum Genet"},{"issue":"1","key":"220_CR24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ng.270","volume":"41","author":"ZA Jenkins","year":"2009","unstructured":"Jenkins ZA et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009;41(1):95\u2013100.","journal-title":"Nat Genet"},{"issue":"1","key":"220_CR25","first-page":"37","volume":"28","author":"P Nurnberg","year":"2001","unstructured":"Nurnberg P et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, results in craniometaphyseal dysplasia. Nat Genet. 2001;28(1):37\u201341.","journal-title":"Nat Genet"},{"issue":"6","key":"220_CR26","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/320612","volume":"68","author":"E Reichenberger","year":"2001","unstructured":"Reichenberger E et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68(6):1321\u20136.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"220_CR27","doi-asserted-by":"crossref","first-page":"e73576","DOI":"10.1371\/journal.pone.0073576","volume":"8","author":"Y Hu","year":"2013","unstructured":"Hu Y et al. A novel autosomal recessive GJA1 missense mutation linked to Craniometaphyseal dysplasia. PLoS One. 2013;8(8):e73576.","journal-title":"PLoS One"},{"issue":"3","key":"220_CR28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/81563","volume":"26","author":"K Janssens","year":"2000","unstructured":"Janssens K et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000;26(3):273\u20135.","journal-title":"Nat Genet"},{"issue":"1","key":"220_CR29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/79128","volume":"26","author":"A Kinoshita","year":"2000","unstructured":"Kinoshita A et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000;26(1):19\u201320.","journal-title":"Nat Genet"},{"issue":"11","key":"220_CR30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/ng1453","volume":"36","author":"J Hellemans","year":"2004","unstructured":"Hellemans J et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet. 2004;36(11):1213\u20138.","journal-title":"Nat Genet"},{"issue":"2","key":"220_CR31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1359\/jbmr.061102","volume":"22","author":"S Mumm","year":"2007","unstructured":"Mumm S et al. Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J Bone Miner Res. 2007;22(2):243\u201350.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"220_CR32","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/ajmg.a.36160","volume":"161A","author":"FK Ababneh","year":"2013","unstructured":"Ababneh FK et al. Hereditary deletion of the entire FAM20C gene in a patient with Raine syndrome. Am J Med Genet A. 2013;161A(12):3155\u201360.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"220_CR33","doi-asserted-by":"crossref","first-page":"e1002708","DOI":"10.1371\/journal.pgen.1002708","volume":"8","author":"X Wang","year":"2012","unstructured":"Wang X et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet. 2012;8(5):e1002708.","journal-title":"PLoS Genet"},{"key":"220_CR34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00003086-198309000-00034","volume":"178","author":"FR Singer","year":"1983","unstructured":"Singer FR, Mills BG. Evidence for a viral etiology of Paget's disease of bone. Clin Orthop Relat Res. 1983;178:245\u201351.","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"220_CR35","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/340731","volume":"70","author":"N Laurin","year":"2002","unstructured":"Laurin N et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1\/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582\u20138.","journal-title":"Am J Hum Genet"},{"issue":"22","key":"220_CR36","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/hmg\/11.22.2735","volume":"11","author":"LJ Hocking","year":"2002","unstructured":"Hocking LJ et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet. 2002;11(22):2735\u20139.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"220_CR37","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2010.11.036","volume":"68","author":"JO Johnson","year":"2010","unstructured":"Johnson JO et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857\u201364.","journal-title":"Neuron"},{"issue":"3","key":"220_CR38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","volume":"347","author":"MP Whyte","year":"2002","unstructured":"Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347(3):175\u201384.","journal-title":"N Engl J Med"},{"issue":"1","key":"220_CR39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/71667","volume":"24","author":"AE Hughes","year":"2000","unstructured":"Hughes AE et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"220_CR40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1359\/jbmr.2002.17.1.26","volume":"17","author":"MP Whyte","year":"2002","unstructured":"Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002;17(1):26\u20139.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"220_CR41","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1359\/jbmr.2000.15.12.2330","volume":"15","author":"MP Whyte","year":"2000","unstructured":"Whyte MP et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J Bone Miner Res. 2000;15(12):2330\u201344.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"220_CR42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2013.03.015","volume":"55","author":"E Boudin","year":"2013","unstructured":"Boudin E et al. No mutations in the serotonin related TPH1 and HTR1B genes in patients with monogenic sclerosing bone disorders. Bone. 2013;55(1):52\u20136.","journal-title":"Bone"},{"issue":"1","key":"220_CR43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bone.2012.09.034","volume":"52","author":"E Boudin","year":"2013","unstructured":"Boudin E et al. Mutations in sFRP1 or sFRP4 are not a common cause of craniotubular hyperostosis. Bone. 2013;52(1):292\u20135.","journal-title":"Bone"},{"key":"220_CR44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2013.11.014","volume":"59","author":"A Pangrazio","year":"2014","unstructured":"Pangrazio A et al. Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis. Bone. 2014;59:122\u20136.","journal-title":"Bone"},{"issue":"2","key":"220_CR45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00198-013-2443-1","volume":"25","author":"S Lazarus","year":"2014","unstructured":"Lazarus S, Zankl A, Duncan EL. Next-generation sequencing: a frameshift in skeletal dysplasia gene discovery. Osteoporos Int. 2014;25(2):407\u201322. Reviews the insights into Sclerosing Bone Dysplasias provided by novel sequencing techniques.","journal-title":"Osteoporos Int"},{"issue":"1","key":"220_CR46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00223-013-9732-8","volume":"93","author":"VM Borra","year":"2013","unstructured":"Borra VM et al. Localization of the gene for hyperostosis cranialis interna to chromosome 8p21 with analysis of three candidate genes. Calcif Tissue Int. 2013;93(1):93\u2013100.","journal-title":"Calcif Tissue Int"},{"key":"220_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bone.2013.10.011","volume":"58","author":"VM Borra","year":"2014","unstructured":"Borra VM et al. Localization of the gene for X-linked calvarial hyperostosis to chromosome Xq27.3-Xqter. Bone. 2014;58:67\u201371.","journal-title":"Bone"},{"issue":"1","key":"220_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1399-0004.1986.tb00773.x","volume":"29","author":"RA Pagon","year":"1986","unstructured":"Pagon RA, Beckwith JB, Ward BH. Calvarial hyperostosis: a benign X-linked recessive disorder. Clin Genet. 1986;29(1):73\u20138.","journal-title":"Clin Genet"},{"issue":"6","key":"220_CR49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1399-0004.2009.01177.x","volume":"75","author":"Y Zhang","year":"2009","unstructured":"Zhang Y et al. Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis. Clin Genet. 2009;75(6):556\u201361.","journal-title":"Clin Genet"},{"issue":"1","key":"220_CR50","first-page":"69","volume":"24","author":"CS Kasapkara","year":"2013","unstructured":"Kasapkara CS et al. An extremely rare case: osteosclerotic metaphyseal dysplasia. Genet Couns. 2013;24(1):69\u201374.","journal-title":"Genet Couns"},{"key":"220_CR51","doi-asserted-by":"crossref","unstructured":"Yao AL, Camacho PM. Osteomesopyknosis: a case report and review of sclerosing bone disorders. Endocr Pract. 2014:1\u201314. doi: 10.4158\/EP13352.CR .","DOI":"10.4158\/EP13352.CR"},{"key":"220_CR52","first-page":"435","volume":"7","author":"S Das","year":"2013","unstructured":"Das S, Crockett JC. Osteoporosis - a current view of pharmacologic prevention and treatment. Drug Des Devel Ther. 2013;7:435\u201348.","journal-title":"Drug Des Devel Ther"},{"key":"220_CR53","doi-asserted-by":"crossref","unstructured":"Leder BZ, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694\u2013700.","DOI":"10.1210\/jc.2013-4440"},{"issue":"7","key":"220_CR54","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1359\/JBMR.040302","volume":"19","author":"S Schaller","year":"2004","unstructured":"Schaller S et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res. 2004;19(7):1144\u201353.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"220_CR55","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.biocel.2012.05.014","volume":"44","author":"A Qin","year":"2012","unstructured":"Qin A et al. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol. 2012;44(9):1422\u201335.","journal-title":"Int J Biochem Cell Biol"},{"issue":"23","key":"220_CR56","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","volume":"95","author":"P Saftig","year":"1998","unstructured":"Saftig P et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95(23):13453\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"220_CR57","doi-asserted-by":"crossref","unstructured":"Duong LT. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Reports, 20. doi: 10.1038\/bonekey.2012.67 .","DOI":"10.1038\/bonekey.2012.67"},{"issue":"11","key":"220_CR58","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"B Langdahl","year":"2012","unstructured":"Langdahl B et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251\u20138.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"220_CR59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-014-0196-1","volume":"12","author":"NA Sims","year":"2014","unstructured":"Sims NA, Ng KW. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep. 2014;12(1):98\u2013106.","journal-title":"Curr Osteoporos Rep"},{"key":"220_CR60","doi-asserted-by":"crossref","unstructured":"Chen M et al. Emerging therapeutic targets for osteoporosis treatment. Expert Opin Ther Target. 2014;18(7):817\u2013831.","DOI":"10.1517\/14728222.2014.912632"},{"key":"220_CR61","first-page":"58","volume":"16C","author":"KW Ng","year":"2014","unstructured":"Ng KW, Martin TJ. New therapeutics for osteoporosis. Curr Opin Pharmacol. 2014;16C:58\u201363.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"220_CR62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.semarthrit.2013.01.004","volume":"43","author":"E Boudin","year":"2013","unstructured":"Boudin E et al. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin Arthritis Rheum. 2013;43(2):220\u201340.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"220_CR63","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412\u201320. The most recent report on the clinical trials of the most promising osteoporosis treatment in development.","journal-title":"N Engl J Med"},{"issue":"211","key":"220_CR64","doi-asserted-by":"crossref","first-page":"211ra158","DOI":"10.1126\/scitranslmed.3006627","volume":"5","author":"R Kedlaya","year":"2013","unstructured":"Kedlaya R et al. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med. 2013;5(211):211ra158.","journal-title":"Sci Transl Med"},{"issue":"1","key":"220_CR65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","volume":"28","author":"BP Sinder","year":"2013","unstructured":"Sinder BP et al. Sclerostin antibody improves skeletal parameters in a Brtl\/+mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28(1):73\u201380. Supports the therapeutic effect of sclerostin antibody in murine model of Osteogenesis Imperfecta. Demonstrates the diversity of this therapeutic agent.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"220_CR66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jbmr.2059","volume":"29","author":"MK Chang","year":"2014","unstructured":"Chang MK et al. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res. 2014;29(1):29\u201342. Comprehensive studies providing insights into the biology of sclerostin inhibition.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"220_CR67","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1210\/jc.2013-3278","volume":"99","author":"AH Lierop van","year":"2014","unstructured":"van Lierop AH et al. Serum Dickkopf 1 levels in sclerostin deficiency. J Clin Endocrinol Metab. 2014;99(2):E252\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"220_CR68","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","volume":"21","author":"F Morvan","year":"2006","unstructured":"Morvan F et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6):934\u201345.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"220_CR69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bmc.2009.11.002","volume":"18","author":"WJ Moore","year":"2010","unstructured":"Moore WJ et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. Bioorg Med Chem. 2010;18(1):190\u2013201.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"220_CR70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/jm801144h","volume":"52","author":"WJ Moore","year":"2009","unstructured":"Moore WJ et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem. 2009;52(1):105\u201316.","journal-title":"J Med Chem"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-014-0220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-014-0220-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-014-0220-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T21:40:38Z","timestamp":1649454038000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-014-0220-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,20]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1007\/s11914-014-0220-5","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,20]]}}}